Sign In
Buy APTO
$1.71
+0 (+0%)
At Close: Jul 25, 2025
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
04:59pm, Thursday, 30'th Nov 2023
SAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing hi
Aptose Biosciences Inc. (APTO) Q3 2023 Earnings Call Transcript
07:22pm, Thursday, 09'th Nov 2023
Aptose Biosciences Inc. (NASDAQ:APTO ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director-Corporate Communications & Investor Relat
Aptose Reports Results for the Third Quarter 2023
04:00pm, Thursday, 09'th Nov 2023
Aptose Reports Results for the Third Quarter 2023 • TUS/VEN Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
09:00am, Thursday, 02'nd Nov 2023
SAN DIEGO and TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing h
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
09:15am, Monday, 30'th Oct 2023
Tusp etinib (TUS) Combination with Venetoclax (VEN) Clinical Findings Highlighted TUS Targets VEN Resistance Mechanisms to Re-sensitize VEN Failure Patients to VEN 44% ORR with TUS/VEN in Difficul
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
07:11am, Thursday, 26'th Oct 2023
SAN DIEGO and TORONTO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted ag
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
07:30am, Monday, 23'rd Oct 2023
SAN DIEGO and TORONTO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing h
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
07:30am, Monday, 16'th Oct 2023
Aptose to present TUS/VEN AML data at ESH; to hold clinical update webcast on October 30th. TUS appears to re-sensitize Prior-VEN failure patients to VEN.
Aptose to Present at the Cantor Global Healthcare Conference
07:45am, Monday, 18'th Sep 2023
SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
07:30am, Thursday, 24'th Aug 2023
SAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing h
Aptose Biosciences Inc. (APTO) Q2 2023 Earnings Call Transcript
11:01pm, Thursday, 10'th Aug 2023
Aptose Biosciences Inc. (NASDAQ:APTO ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Corporate Communications and Investor Relations William Rice
3 Stocks With 1,000% Upside Potential
10:03am, Sunday, 21'st May 2023
If you're a risk taker on the lookout for stocks with 1000% upside potential, you'd have to venture into speculative territory. It is difficult to find analyst ratings with such a high upside potentia
Aptose Biosciences Inc. (APTO) Q1 2023 Earnings Call Transcript
09:22pm, Monday, 08'th May 2023
Aptose Biosciences Inc. (NASDAQ:APTO ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Susan Pietropaolo – Corporate Communications & Investor Relations William G. Rice
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
07:01am, Thursday, 04'th May 2023
SAN DIEGO and TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted ag
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
07:01am, Monday, 24'th Apr 2023
SAN DIEGO and TORONTO, April 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted
